ALNY vs. ARGX: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALNY and ARGX, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
With ALNY at 38.15 billion USD and ARGX at 35.72 billion USD, their market capitalizations sit in the same ballpark.
With betas of 0.17 for ALNY and 0.17 for ARGX, both show similar volatility profiles relative to the overall market.
ARGX is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike ALNY, which is purely domestic.
| Symbol | ALNY | ARGX |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | argenx SE |
| Country | US | NL |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. | Mr. Timothy Van Hauwermeiren EMBA, M.Sc. |
| Price | 292.58 USD | 584.95 USD |
| Market Cap | 38.15 billion USD | 35.72 billion USD |
| Beta | 0.17 | 0.17 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | June 1, 2004 | May 18, 2017 |
| ADR | No | Yes |
Performance Comparison
This chart compares the performance of ALNY and ARGX over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALNY and ARGX based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALNY posts a negative P/E of -140.68, reflecting last year’s net loss, while ARGX at 51.08 signals healthy earnings.
- ALNY posts a negative forward PEG of -38.16, hinting at anticipated earnings decline, whereas ARGX at 1.35 has projections for stable or growing earnings.
- ALNY and ARGX both consumed more free cash flow than they generated last year—P/FCF of -506.05 and -455.95, respectively—highlighting persistent liquidity pressure.
| Symbol | ALNY | ARGX |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -140.68 | 51.08 |
| Forward PEG Ratio (TTM) | -38.16 | 1.35 |
| Price-to-Sales Ratio (P/S, TTM) | 16.25 | 16.50 |
| Price-to-Book Ratio (P/B, TTM) | 328.68 | 7.75 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -506.05 | -455.95 |
| EV-to-EBITDA (TTM) | -251.73 | 4572.56 |
| EV-to-Sales (TTM) | 16.37 | 15.84 |
| EV-to-Free Cash Flow (TTM) | -509.80 | -437.78 |
Dividend Comparison
Neither ALNY nor ARGX currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ALNY | ARGX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALNY and ARGX, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ALNY is heavily leveraged (debt-to-equity ratio 11.28), which can boost returns but raises risk if borrowing costs climb, while ARGX at 0.01 keeps leverage at a more moderate level.
- Both ALNY and ARGX report negative interest coverage ratios (-0.79, -20.85), meaning EBIT itself is negative—neither can cover interest, a critical solvency warning.
| Symbol | ALNY | ARGX |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 7.29 |
| Quick Ratio (TTM) | 2.98 | 6.68 |
| Debt-to-Equity Ratio (TTM) | 11.28 | 0.01 |
| Debt-to-Assets Ratio (TTM) | 0.31 | 0.01 |
| Interest Coverage Ratio (TTM) | -0.79 | -20.85 |